COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma
COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma
Safety follow-up of the randomized, phase 3 study DESTINY-Breast03
Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC
High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma
Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3 DETERMINATION trial
Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-deficient locally advanced rectal cancer
Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer
Ibrutinib improves PFS by 50% for older patients with newly diagnosed mantle cell lymphoma
N-803-BCG combination shows promising results in BCG-unresponsive NMIBC
Sacituzumab goviteca provides clinically meaningful PFS benefit for hormone receptor HR+/HER2‐ advanced breast cancer patients
UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries
ASCO and WHO to collaborate on quality indicators for cancer facilities